§ 866.3181. Cytomegalovirus nucleic acid detection device for congenital cytomegalovirus infection.
496 words·~2 min read·
/us/cfr/t21/s§ 866.3181·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Identification. A cytomegalovirus nucleic acid detection device for congenital cytomegalovirus infection is an in vitro diagnostic device intended for the qualitative detection of cytomegalovirus DNA in clinical samples from newborn babies to aid in the diagnosis of congenital cytomegalovirus infection. Negative results do not preclude infection and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results should be interpreted with consideration of other clinical information and laboratory findings and should not be used as the sole basis for treatment or other patient management decisions.
(b)Classification. Class II (special controls). The special controls for this device are:
(1)The labeling required under § 809.10(b) of this chapter must include:
(i)An intended use with a detailed description of what the device detects, the type of results provided to the user, the clinical indications appropriate for test use, and the specific population(s) to be tested.
(ii)A detailed device description, including all device components, instrument requirements, ancillary reagents required but not provided, and an explanation of the methodology, including all pre-analytical methods for specimen processing.
(iii)Performance characteristics from analytical and clinical studies required under paragraphs (b)(2)(ii) and
(iii)of this section.
(iv)A detailed explanation of the interpretation of results and criteria for validity of results.
(v)A limiting statement that device results are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions.
(vi)As applicable, a limiting statement and specific sample collection recommendations to indicate that breast milk can result in false positive results for saliva samples if samples are collected less than 1 hour after breastfeeding. Sample collection a minimum of 1 hour from breastfeeding must be recommended.
(vii)Detailed instructions for use that minimize the risk of generating a false result.
(2)Design verification and validation must include:
(i)Detailed device description documentation, including methodology from obtaining sample to result, design of primer/probe sequences, rationale for sequence selection, and computational path from collected raw data to reported result (e.g., how collected raw signals are converted into a reported result).
(ii)Detailed documentation of analytical studies including characterization of the cutoff, analytical sensitivity (limit of detection), inclusivity, reproducibility, interference, cross reactivity, instrument and method carryover/cross contamination, and sample stability and handling.
(iii)Detailed documentation from a clinical study documenting sensitivity and specificity of the device; if the number of positive samples in the clinical study is insufficient to properly estimate device sensitivity, additional pre-selected positive samples must be evaluated to supplement the study. Clinical study subjects must be consistent with the intended use population (i.e., infants younger than 21 days of age), and device results must be compared to FDA-accepted comparator methods. Documentation from the clinical study must include the clinical study protocol, the clinical study report, testing results, and results of all statistical analyses.
(iv)Detailed documentation for device software, including software applications and hardware-based devices that incorporate software. [90 FR 19636, May 9, 2025]
Connections9 cite this
Cited by 9 sections · top 1
Citation graph
cites case law
§ 866.3181
Cytomegalovirus nucleic acid detection device for congenital cytomegalovirus infection.
Fed. Reg.×9
Cites 0Cited by 9 across 1 source